PRESS RELEASE
China Eye Valley and Skyline Therapeutics sign memorandum of understanding to jointly advance ocular gene therapy practices
January 10, 2022

Wenzhou, Zhejiang, China, January 10, 2022 – China Eye Valley and Skyline Therapeutics signed a memorandum of understanding (MoU) today at China Eye Valley in Wenzhou, Zhejiang province. Following the MoU signage, the two organizations also held an unveiling ceremony for the China Eye Valley-Skyline Therapeutics Gene Therapy Translational Research Center. Scientific leaders from both parties also discussed the latest progress and innovations in gene therapy, including the current standard of care and ocular disease patients’ unmet clinical needs.


The strategic partnership between China Eye Valley and Skyline Therapeutics aims at advancing scientific and clinical research in the ophthalmology therapeutic area to address unfulfilled medical needs, with a focus on the role of the cutting-edge science and technology of gene therapy. By signing the MoU, China Eye Valley and Skyline Therapeutics are committed to jointly facilitating the development and application of advanced gene therapy to benefit ophthalmic patients.


Professor Qu Jia, Chairman of the China Eye Valley Council and Director of the Wenzhou International Innovation Center for Optometry, as well as a pioneer in optometry education and medical care in China, said: "Gene therapy is the next frontier of biomedical development. It is expected to bring a new direction to treat different diseases, including ocular disorders. Skyline Therapeutics is a gene therapy company with a world-class R&D team and innovation capabilities. Our cooperation with Skyline Therapeutics illustrates that China Eye Valley is taking a major step forward in its journey to pursue innovation and bring together the world's most advanced scientific concepts and technology. Our goal is to integrate the advantages of technology enterprises, medical institutions and industry clusters to support knowledge and talent development, laying a solid foundation for lasting innovations in ocular medical treatment."

 

About China Eye Valley

China Eye Valley is an ophthalmology industry park jointly built by Wenzhou National High-Tech Zone and the Eye Hospital of Wenzhou Medical University, one of China’s top ophthalmology research institutes. It aims to create an ecosystem that brings together advanced concepts and solutions in the visual and eye care space around the world to promote the scientific and technological innovation and industrial development in the field of ophthalmology. www.eyevalley.org

 

About Skyline Therapeutics

Skyline Therapeutics is a fully integrated gene and cell therapy company dedicated to the discovery, development and delivery of innovative therapies. Established in 2019, Skyline Therapeutics has built a proprietary AAV-based gene therapy platform that integrates novel capsid engineering and vector design, analytical and process development, and state-of-the-art GMP manufacturing capabilities that support large scale clinical-grade vector production. The Skyline team of world-class experts and leaders in science, technology and business brings industry-leading know-how and is advancing a pipeline of diversified programs that address multiple diseases including ocular, neurological, metabolic and blood disorders. Skyline Therapeutics is also broadening its therapeutic expertise to cover more disease areas with high unmet need such as cardiovascular disorders through strategic partnerships. Headquartered in China, Skyline Therapeutics currently has research, development and manufacturing capabilities in Shanghai and Hangzhou. www.skytx.com


Adapted version.